KNSA Stock Overview
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Kiniksa Pharmaceuticals, Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.44|
|52 Week High||US$15.25|
|52 Week Low||US$7.36|
|1 Month Change||17.48%|
|3 Month Change||21.41%|
|1 Year Change||23.19%|
|3 Year Change||90.10%|
|5 Year Change||n/a|
|Change since IPO||-30.97%|
Recent News & Updates
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA ) shareholders will have a reason to smile today, with the analysts making...
Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q2 GAAP EPS of -$0.29 beats by $0.15. Revenue of $26.97M (+250.3% Y/Y) misses by $1.58M. As of June 30, 2022, the company had $138.2 million of cash, cash equivalents, and short-term investments, and no debt. Kiniksa continues to expect ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million vs consensus of $133.8M. Shares +10% PM.
|KNSA||US Biotechs||US Market|
Return vs Industry: KNSA exceeded the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: KNSA exceeded the US Market which returned -23.2% over the past year.
|KNSA Average Weekly Movement||8.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: KNSA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: KNSA's weekly volatility (9%) has been stable over the past year.
About the Company
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. Fundamentals Summary
|KNSA fundamental statistics|
Is KNSA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KNSA income statement (TTM)|
|Cost of Revenue||US$28.64m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.61|
|Net Profit Margin||-124.52%|
How did KNSA perform over the long term?See historical performance and comparison